Subjective memory impairment and cholinergic transmission: a TMS study

Area of Science:

• Neuroscience
• Neurology
• Cognitive Science

Background:

• Subjective memory impairment (SMI) is increasingly recognized as a preclinical stage of Alzheimer disease (AD).
• Short latency afferent inhibition (SAI) assesses central cholinergic circuit function and is abnormal in AD and amnestic mild cognitive impairment.
• Identifying preclinical AD biomarkers is crucial for early intervention.

Purpose of the Study:

• To investigate the utility of SAI as a biomarker in individuals with Subjective Memory Impairment (SMI).
• To determine if SAI is abnormal in SMI subjects, indicating cholinergic dysfunction.

Main Methods:

• Recruited 20 subjects experiencing Subjective Memory Impairment (SMI).
• Measured Short Latency Afferent Inhibition (SAI) in all participants.
• Compared SAI results in SMI subjects to established findings in AD and MCI.

Main Results:

• Short Latency Afferent Inhibition (SAI) was found to be normal in the 20 subjects with Subjective Memory Impairment (SMI).
• This finding contrasts with previous reports of abnormal SAI in Alzheimer disease (AD) and amnestic mild cognitive impairment.

Conclusions:

• Normal SAI in SMI subjects suggests it may not be a universal marker for early cholinergic degeneration in this population.
• SAI could potentially serve as a biomarker to identify individuals with memory complaints who exhibit cholinergic degeneration, differentiating them from those without.